Trublood is a minimally invasive, diagnostic test that can clearly identify cancer in symptomatic patients. Trublood provides diagnostic information similar to that of a tissue biopsy when it is inconclusive or not possible. Based on the test result, therapy can be aligned.
Trublood is available exclusively at Hill Clinic - an official representative of Datar Cancer Genetics. It was developed by Datar Cancer Genetics based on the results of several clinical studies and validated on more than 40,000 samples. These included samples from asymptomatic subjects undergoing screening tests such as mammograms, colonoscopies, PAP smears, serum CA markers and other clinical examinations, as well as more than 17,000 samples from patients with various cancers and patients with benign diseases.
Who is the Trublood™ test for?
symptomatic patients but the organ is difficult to access
symptomatic individuals who have been advised an invasive tissue biopsy to check for mailgnancy
patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations
The cutting-edge technology that powers Trublood™ is validated stringently to meet global standards.
Trublood in comparison with tissue biopsy
No pain, no stitches, no scars; only one blood draw
No risk of tumour cell seeding
No risk of injury to any organ / bleeding
Suitable for radiologically undetectable tumors.
Viable even if primary / metastasis are undetectable
Provides real time data and covers all active sites Can be performed as often as necessary
The US Food and Drug Administration (FDA) has declared Datar Cancer Genetics' tests a breakthrough in medical technology of special significance.
A blood biopsy detects circulating tumor cells (CTCs) and clusters of these cells separated from malignant tumors. Trucheck uses an epigenetically activating environment (EAM) that negatively enriches CTCs through the hallmark cancer evasion mechanism of apoptosis. When isolated PBMCs are treated with EAM, all non-malignant cells are eliminated, while all malignant cells, cells existing in the body tumor (CTCs), survive. These circulating tumor cell CTCs can be found in cancer patients and do not exist in healthy people. A blood biopsy can determine which organ these cells come from, ie. indicates the exact location of the tumor. Detected cancer cells are examined for number, size and characteristics, and the whole process takes only a few days. Blood biopsy enables extremely fast diagnosis and corresponding treatment of cancer in the earliest phase, which gives an optimal prognosis for the patient's survival.
AN ORGAN-SPECIFIC TEST CAN BE DONE ON:
централна нервна система – глиома
Trublood can complement, or if necessary, replace invasive biopsies.